title: Effect of topical tafluprost on optic nerve head blood flow in patients with myopic disc type.
abstract: OBJECTIVE
  To investigate the effect of topical tafluprost on optic disc blood flow in patients with myopic disc.
  
  
  METHODS
  Forty-eight eyes in 24 patients with a myopic disc type (oval shaped) optic disc tilted to the temporal, with a crescent peripapillary atrophy were included in this study. Twenty-eight eyes were diagnosed as normal tension glaucoma and 20 eyes were in normal subjects. None had any treatment for glaucoma. Average age was 45.3±11.9 years. One eye was treated with topical tafluprost and the fellow eye served as the control. Ocular blood flow was measured by laser speckle flowgraphy (LSFG-NAVI) at 30, 60, 90, and 120 minutes after tafluprost administration, and the mean blur rate (MBR) on the optic disc was analyzed. Blood pressure and intraocular pressure (IOP) were recorded.
  
  
  RESULTS
  In all subjects, topical tafluprost (a) significantly reduced IOP versus baseline from 60 minutes after treatment (baseline: 15.2±3.4 mm Hg, 60 min: 13.3±3.2 mm Hg, P=0.001, 90 min: 13.3±3.6 mm Hg, P=0.002, 120 min: 13.7±3.4 mm Hg, P=0.007); and (b) significantly increased the MBR versus baseline (60 min: +4.3±6.6%, P=0.008, 90 min: +5.0±4.9%, P<0.001, 120 min: +6.7±7.0%, P<0.001).
  
  
  CONCLUSIONS
  Topical tafluprost increased MBR in the optic nerve head and significantly reduced IOP, effects that may represent beneficial treatment for glaucoma patients with a myopic disc type.
authors.affiliation: Department of Ophthalmology, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan.
authors.forename: Satoru
authors.initials: S
authors.lastname: Tsuda
authors.forename: Yu
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: Naoki
authors.initials: N
authors.lastname: Chiba
authors.forename: Naoko
authors.initials: N
authors.lastname: Aizawa
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Shiga
authors.forename: Masayuki
authors.initials: M
authors.lastname: Yasuda
authors.forename: Shunji
authors.initials: S
authors.lastname: Yokokura
authors.forename: Takaaki
authors.initials: T
authors.lastname: Otomo
authors.forename: Nobuo
authors.initials: N
authors.lastname: Fuse
authors.forename: Toru
authors.initials: T
authors.lastname: Nakazawa
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000502:physiology; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D017078:Laser-Doppler Flowmetry; D057066:Low Tension Glaucoma / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000503:physiopathology*; D009883:Ophthalmic Solutions; D009898:Optic Disk / Q000098:blood supply*; D011460:Prostaglandins F / Q000008:administration & dosage / Q000627:therapeutic use*; D012039:Regional Blood Flow / Q000187:drug effects; D012171:Retinal Vessels / Q000503:physiopathology*; D041623:Tomography, Optical Coherence; D014065:Tonometry, Ocular
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011460:Prostaglandins F; C485333:tafluprost